In The News,
ADVI’s Lindsay Bealor Greenleaf discussed the White House’s decision to withdraw the anticipated rebate rule aimed at reforming the drug supply chain and lowering prescription out-of-pocket costs
[el-text]
Written by Steven Porter
***excerpt***
“This is very disappointing, and means pharmacy benefit managers and other middlemen in the supply chain will continue to inflate prescription drug prices,” Greenleaf said in a statement. “Interactions with middlemen throughout the supply chain is why manufacturers retain less than 60% of total spending on prescription drugs.”
***end excerpt***
[/el-text]